Your browser doesn't support javascript.
loading
Vaccine effectiveness against influenza hospitalisation in adults during the 2022/2023 mixed season of influenza A(H1N1)pdm09, A(H3N2) and B circulation, Europe: VEBIS SARI VE hospital network.
Rose, Angela M C; Pozo, Francisco; Martínez-Baz, Iván; Mazagatos, Clara; Bossuyt, Nathalie; Cauchi, John Paul; Petrovic, Goranka; Loghin, Isabela I; Vaikutyte, Roberta; Buda, Silke; Machado, Ausenda; Duffy, Róisín; Oroszi, Beatrix; Howard, Jennifer; Echeverria, Aitziber; Andreu, Cristina; Barbezange, Cyril; Dziugyte, Ausra; Nonkovic, Diana; Popescu, Corneliu-Petru; Majauskaite, Fausta; Tolksdorf, Kristin; Gomez, Verónica; Domegan, Lisa; Horváth, Judit Krisztina; Castilla, Jesús; García, Miriam; Demuyser, Thomas; Borg, Maria-Louise; Tabain, Irena; Lazar, Mihaela; Kubiliute, Ieva; Dürrwald, Ralf; Guiomar, Raquel; O'Donnell, Joan; Kristóf, Katalin; Nicolay, Nathalie; Bacci, Sabrina; Kissling, Esther.
Afiliação
  • Rose AMC; Epiconcept, Paris, France.
  • Pozo F; National Centre for Microbiology, Institute of Health Carlos III, Madrid, Spain.
  • Martínez-Baz I; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.
  • Mazagatos C; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.
  • Bossuyt N; Instituto de Salud Pública de Navarra-IdiSNA, Pamplona, Spain.
  • Cauchi JP; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.
  • Petrovic G; National Centre for Epidemiology, Institute of Health Carlos III, Madrid, Spain.
  • Loghin II; Sciensano, Brussels, Belgium.
  • Vaikutyte R; Department for Health Regulation, Health Promotion and Disease Prevention, Msida, Malta.
  • Buda S; Croatian Institute of Public Health, Zagreb, Croatia.
  • Machado A; St Parascheva Clinical Hospital of Infectious Diseases, Iasi, Romania.
  • Duffy R; Lithuanian University of Health Sciences, Kaunas, Lithuania.
  • Oroszi B; Robert Koch Institute, Berlin, Germany.
  • Howard J; National Institute of Health Dr Ricardo Jorge, Lisbon, Portugal.
  • Echeverria A; Health Service Executive-Health Protection Surveillance Centre, Dublin, Ireland.
  • Andreu C; Semmelweis University, Budapest, Hungary.
  • Barbezange C; Epiconcept, Paris, France.
  • Dziugyte A; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.
  • Nonkovic D; Instituto de Salud Pública de Navarra-IdiSNA, Pamplona, Spain.
  • Popescu CP; Subdirección de Epidemiología, Dirección General de Salud Pública, Servicio Extremeño de Salud, Mérida, Spain.
  • Majauskaite F; Sciensano, Brussels, Belgium.
  • Tolksdorf K; Department for Health Regulation, Health Promotion and Disease Prevention, Msida, Malta.
  • Gomez V; Teaching Public Health Institute of Split-Dalmatia County, Split, Croatia.
  • Domegan L; Dr Victor Babes Clinical Hospital of Infectious and Tropical Diseases, Bucharest, Romania.
  • Horváth JK; Institute of Clinical Medicine, Medical Faculty, Vilnius University, Vilnius, Lithuania.
  • Castilla J; Robert Koch Institute, Berlin, Germany.
  • García M; National Institute of Health Dr Ricardo Jorge, Lisbon, Portugal.
  • Demuyser T; Health Service Executive-Health Protection Surveillance Centre, Dublin, Ireland.
  • Borg ML; Semmelweis University, Budapest, Hungary.
  • Tabain I; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.
  • Lazar M; Instituto de Salud Pública de Navarra-IdiSNA, Pamplona, Spain.
  • Kubiliute I; Dirección General de Salud Pública, Departamento de Sanidad, Gobierno de Aragón, Zaragoza, Spain.
  • Dürrwald R; Department of Microbiology and Infection control, UZ Brussel, Brussels, Belgium.
  • Guiomar R; Department for Health Regulation, Health Promotion and Disease Prevention, Msida, Malta.
  • O'Donnell J; Croatian Institute of Public Health, Zagreb, Croatia.
  • Kristóf K; "Cantacuzino" National Military-Medical Institute for Research and Development, Bucharest, Romania.
  • Nicolay N; Institute of Clinical Medicine, Medical Faculty, Vilnius University, Vilnius, Lithuania.
  • Bacci S; Robert Koch Institute, Berlin, Germany.
  • Kissling E; National Institute of Health Dr Ricardo Jorge, Lisbon, Portugal.
Influenza Other Respir Viruses ; 18(2): e13255, 2024 Feb.
Article em En | MEDLINE | ID: mdl-38403302
ABSTRACT
We conducted a multicentre hospital-based test-negative case-control study to measure vaccine effectiveness (VE) against PCR-confirmed influenza in adult patients with severe acute respiratory infection (SARI) during the 2022/2023 influenza season in Europe. Among 5547 SARI patients ≥18 years, 2963 (53%) were vaccinated against influenza. Overall VE against influenza A(H1N1)pdm09 was 11% (95% CI -23-36); 20% (95% CI -4-39) against A(H3N2) and 56% (95% CI 22-75) against B. During the 2022/2023 season, while VE against hospitalisation with influenza B was >55%, it was ≤20% for influenza A subtypes. While influenza vaccination should be a priority for future seasons, improved vaccines against influenza are needed.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pneumonia / Vacinas contra Influenza / Influenza Humana / Vírus da Influenza A Subtipo H1N1 Limite: Adult / Humans País/Região como assunto: Europa Idioma: En Revista: Influenza Other Respir Viruses Assunto da revista: VIROLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: França
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pneumonia / Vacinas contra Influenza / Influenza Humana / Vírus da Influenza A Subtipo H1N1 Limite: Adult / Humans País/Região como assunto: Europa Idioma: En Revista: Influenza Other Respir Viruses Assunto da revista: VIROLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: França